X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1007) 1007
Book Review (123) 123
Publication (116) 116
Conference Proceeding (91) 91
Patent (23) 23
Book / eBook (11) 11
Book Chapter (10) 10
Web Resource (8) 8
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (610) 610
index medicus (601) 601
oncology (498) 498
female (359) 359
male (325) 325
middle aged (317) 317
adult (263) 263
aged (255) 255
cancer (202) 202
treatment outcome (144) 144
neoplasms - drug therapy (131) 131
antineoplastic agents - therapeutic use (128) 128
aged, 80 and over (111) 111
abridged index medicus (108) 108
mutation (101) 101
article (86) 86
tumors (84) 84
antineoplastic combined chemotherapy protocols - therapeutic use (82) 82
research (80) 80
therapy (78) 78
care and treatment (74) 74
chemotherapy (74) 74
young adult (71) 71
neoplasms - pathology (69) 69
hematology (67) 67
neoplasms - genetics (67) 67
prognosis (65) 65
solid tumors (65) 65
clinical trials (64) 64
adolescent (61) 61
molecular targeted therapy (60) 60
antineoplastic agents - adverse effects (57) 57
expression (57) 57
dose-response relationship, drug (55) 55
animals (54) 54
maximum tolerated dose (54) 54
antineoplastic combined chemotherapy protocols - adverse effects (53) 53
breast-cancer (51) 51
disease-free survival (51) 51
cell lung-cancer (49) 49
bevacizumab (48) 48
retrospective studies (47) 47
survival (46) 46
targeted therapy (46) 46
mutations (44) 44
patients (44) 44
antineoplastic agents - administration & dosage (43) 43
medicine & public health (43) 43
neoplasms - metabolism (42) 42
drug therapy (41) 41
melanoma (41) 41
protein kinase inhibitors - therapeutic use (41) 41
metastasis (40) 40
neoplasm staging (40) 40
immunotherapy (39) 39
drug administration schedule (38) 38
pharmacology & pharmacy (38) 38
clinical trials, phase i as topic (36) 36
analysis (35) 35
colorectal-cancer (35) 35
neoplasms (35) 35
antineoplastic agents (34) 34
antineoplastic agents - pharmacology (34) 34
genetic aspects (34) 34
leukemia (34) 34
medicine, general & internal (33) 33
phase-i (33) 33
carcinoma (32) 32
clinical trials as topic (32) 32
pharmacology/toxicology (32) 32
angiogenesis (31) 31
precision medicine (31) 31
time factors (31) 31
resistance (30) 30
survival rate (30) 30
antineoplastic combined chemotherapy protocols - administration & dosage (29) 29
apoptosis (29) 29
cell biology (29) 29
neoplasms - therapy (29) 29
biomarkers, tumor - genetics (28) 28
chronic myelogenous leukemia (28) 28
hematology, oncology and palliative medicine (28) 28
medicine (28) 28
child (27) 27
dermatology (27) 27
health aspects (27) 27
kaplan-meier estimate (27) 27
phosphatidylinositol 3-kinases - genetics (27) 27
renal-cell carcinoma (27) 27
chronic myeloid-leukemia (26) 26
disease progression (26) 26
multivariate analysis (26) 26
neoplasms - mortality (26) 26
pathway (26) 26
phase i (26) 26
protein kinase inhibitors - administration & dosage (26) 26
antibodies, monoclonal - therapeutic use (25) 25
biopsy (25) 25
proto-oncogene proteins b-raf - genetics (25) 25
survival analysis (25) 25
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncology (Williston Park, N.Y.), ISSN 0890-9091, 04/2018, Volume 32, Issue 4, pp. 150 - 163
In August 2017, Drs. Kurzrock and Kato and colleagues published a study[1] analyzing potential genetic biomarkers of so-called "hyperprogressors"-cancer... 
ONCOLOGY | Development and progression | Endometrial cancer | Sarcoma | Immunotherapy | Index Medicus
Journal Article
Oncology, ISSN 0890-9091, 01/2018, Volume 32, Issue 1, p. 2
Journal Article
INTERNATIONAL JOURNAL OF ONCOLOGY, ISSN 1019-6439, 03/2009, Volume 34, Issue 3, pp. 595 - 595
Journal Article
11/2017, Current Cancer Research Ser., ISBN 9783319637563
Annotation This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial... 
Medical | Cancer
Web Resource
2008, Current clinical oncology, ISBN 9781603274234, xii, 445
Emerging technologies in target identification, drug discovery, molecular markers, and imaging are rapidly changing the face of cancer. Targeted Cancer Therapy... 
drug therapy | Neoplasms | Drug Design | Drug Delivery Systems | Clinical & internal medicine | Cancer | Drug targeting | Treatment | Oncology | Cancer Research | Internal Medicine | Medicine & Public Health | Hematology
Book
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | SURVIVAL | IRRADIATION | MEDICINE, GENERAL & INTERNAL | PATHWAY | RAF INHIBITOR RESISTANCE | B-RAF | MUTATIONS | CANCER | BRAF(V600E) | VEMURAFENIB | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
1995, Volume 13, no. 1., xxi, 243
Book
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4242 - 4250
Journal Article
1993, Volume 11, no. 1., 187
Book
Cancer Cell, ISSN 1535-6108, 02/2019, Volume 35, Issue 2, pp. 157 - 160
Journal Article
Web Resource
Web Resource
Web Resource
2008, Current clinical oncology, ISBN 9781603274234
Web Resource
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 782 - 789
Summary Background MEK is a member of the MAPK signalling cascade that is commonly activated in melanoma. Direct inhibition of MEK blocks cell proliferation... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | BRAF | ONCOLOGY | RAF | SOMATIC MUTATIONS | PROGRESSION | Skin Neoplasms - drug therapy | United States | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Uveal Neoplasms - enzymology | Young Adult | Pyridones - administration & dosage | Skin Neoplasms - enzymology | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Uveal Neoplasms - genetics | Uveal Neoplasms - pathology | Drug Administration Schedule | Administration, Oral | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Treatment Outcome | MAP Kinase Kinase 2 - metabolism | Melanoma - pathology | Uveal Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | MAP Kinase Kinase 2 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Uveal Neoplasms - mortality | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Prevention | Care and treatment | Melanoma | Cancer | Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 773 - 781
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.